

# Zobair M Younossi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2066308/publications.pdf>

Version: 2024-02-01

614  
papers

81,563  
citations

1233

110  
h-index

507

268  
g-index

624  
all docs

624  
docs citations

624  
times ranked

43110  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 73-84.	3.6	7,346
2	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	3.6	4,738
3	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 11-20.	8.2	3,487
4	Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. <i>Gastroenterology</i> , 1999, 116, 1413-1419.	0.6	3,005
5	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023.	3.6	2,935
6	Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 274-285.	1.9	2,569
7	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
8	The utility of radiological imaging in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2002, 123, 745-750.	0.6	1,749
9	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	13.9	1,605
10	Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. <i>Gastroenterology</i> , 2015, 148, 547-555.	0.6	1,506
11	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.	0.6	1,486
12	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018, 67, 123-133.	3.6	1,474
13	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	13.9	1,466
14	Non-alcoholic fatty liver disease — A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	1.8	1,345
15	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	3.6	1,294
16	The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 793-801.	1.8	1,253
17	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
18	Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 524-530.e1.	2.4	933

#	ARTICLE	IF	CITATIONS
19	The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. <i>Hepatology</i> , 2016, 64, 1577-1586.	3.6	894
20	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
21	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014, 384, 1756-1765.	6.3	751
22	Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 234-238.	2.4	643
23	Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. <i>Hepatology</i> , 2015, 62, 1723-1730.	3.6	633
24	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	0.6	575
25	Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008, 49, 608-612.	1.8	567
26	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
27	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.	3.6	531
28	Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. <i>Gut</i> , 1999, 45, 295-300.	6.1	529
29	Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. <i>Seminars in Liver Disease</i> , 2001, 21, 017-026.	1.8	526
30	Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. <i>Hepatology</i> , 2011, 53, 1874-1882.	3.6	525
31	Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. <i>Medicine (United States)</i> , 2012, 91, 319-327.	0.4	441
32	Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. <i>Hepatology</i> , 2020, 72, 1605-1616.	3.6	431
33	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. <i>Clinics in Liver Disease</i> , 2016, 20, 205-214.	1.0	403
34	Epidemiology and Natural History of NAFLD and NASH. <i>Clinics in Liver Disease</i> , 2007, 11, 1-16.	1.0	388
35	Nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 262-265.	2.4	378
36	Adipokines and cytokines in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 412-421.	1.9	364

#	ARTICLE	IF	CITATIONS
37	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012, 107, 811-826.	0.2	359
38	Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17006.	18.1	354
39	Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1017-1025.	1.5	339
40	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
41	Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. <i>Hepatology</i> , 2005, 41, 790-800.	3.6	329
42	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	1.1	323
43	Epidemiology of chronic liver diseases in the USA in the past three decades. <i>Gut</i> , 2020, 69, 564-568.	6.1	321
44	Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. <i>Gastroenterology</i> , 2016, 150, 1599-1608.	0.6	315
45	Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 646-650.	2.4	297
46	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019, 103, 22-27.	0.5	296
47	Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2263-2271.	0.2	294
48	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
49	Health-related quality of life in chronic liver disease: the impact of type and severity of disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2199-2205.	0.2	281
50	Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2005, 15, 310-315.	1.1	276
51	Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 721-728.	0.6	275
52	Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1224-1229.e2.	2.4	270
53	Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 580-589.e5.	2.4	269
54	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021, 73, 1194-1198.	3.6	266

#	ARTICLE	IF	CITATIONS
55	A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). <i>Obesity Surgery</i> , 2008, 18, 1430-1437.	1.1	255
56	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
57	Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. <i>Gastroenterology</i> , 2016, 150, 1778-1785.	0.6	251
58	AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2021, 160, 912-918.	0.6	245
59	Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. <i>Gut</i> , 2010, 59, 1410-1415.	6.1	239
60	Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2001, 7, 797-801.	1.3	236
61	Non-Invasive markers for hepatic fibrosis. <i>BMC Gastroenterology</i> , 2011, 11, 91.	0.8	236
62	Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Digestive Diseases and Sciences</i> , 2013, 58, 3017-3023.	1.1	236
63	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
64	Disease Burden of Hepatocellular Carcinoma: A Global Perspective. <i>Digestive Diseases and Sciences</i> , 2019, 64, 910-917.	1.1	223
65	Nonalcoholic fatty liver disease: An agenda for clinical research. <i>Hepatology</i> , 2002, 35, 746-752.	3.6	216
66	Hepatic iron and nonalcoholic fatty liver disease. <i>Hepatology</i> , 1999, 30, 847-850.	3.6	212
67	A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 665-674.	3.6	209
68	Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. <i>Modern Pathology</i> , 1998, 11, 560-5.	2.9	209
69	The role of liver biopsy in chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 196-200.	3.6	208
70	Hepatitis C, interferon alfa, and depression. <i>Hepatology</i> , 2000, 31, 1207-1211.	3.6	198
71	Nonalcoholic fatty liver disease (<sc>NAFLD</sc>) is associated with low level of physical activity: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 772-781.	1.9	197
72	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197

#	ARTICLE	IF	CITATIONS
73	In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1034-1041.e1.	2.4	196
74	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2915-2922.	1.1	192
75	Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. <i>Medicine (United States)</i> , 2017, 96, e5904.	0.4	181
76	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.2	165
77	The effects of HCV infection and management on health-related quality of life. <i>Hepatology</i> , 2007, 45, 806-816.	3.6	162
78	Cost effectiveness of interferon $\beta$ combined with ribavirin for the treatment of chronic hepatitis C. <i>Hepatology</i> , 1999, 30, 1318-1324.	3.6	158
79	Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 497-520.	1.9	157
80	Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019, 69, 1064-1074.	3.6	154
81	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. <i>Hepatology Communications</i> , 2019, 3, 1459-1471.	2.0	150
82	Adipose Tissue as an Endocrine Organ. <i>Clinics in Liver Disease</i> , 2014, 18, 41-58.	1.0	148
83	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. <i>Journal of Hepatology</i> , 2015, 63, 337-345.	1.8	148
84	Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1017-1029.	2.4	147
85	Review article: current management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 2-12.	1.9	146
86	A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. <i>Obesity Surgery</i> , 2011, 21, 431-439.	1.1	143
87	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). <i>Medicine (United States)</i> , 2018, 97, e0214.	0.4	143
88	Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. <i>Hepatology</i> , 2019, 69, 564-572.	3.6	142
89	In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 352-360.	1.5	141
90	Predictors of health-related quality of life in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 469-476.	1.9	140

#	ARTICLE	IF	CITATIONS
91	Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. <i>Human Pathology</i> , 2004, 35, 196-199.	1.1	139
92	Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2531-2539.	1.1	139
93	Cholestatic Liver Diseases and Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2000, 95, 497-502.	0.2	137
94	Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. <i>Liver</i> , 2001, 21, 266-271.	0.1	137
95	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. <i>Hepatology</i> , 2004, 40, 1450-1458.	3.6	136
96	Associations of chronic hepatitis C with metabolic and cardiac outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 647-652.	1.9	134
97	Assessment of Utilities and Health-Related Quality of Life in Patients With Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 579-583.	0.2	133
98	Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2016, 22, 6318.	1.4	131
99	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION1, 2, and 3 clinical trials. <i>Hepatology</i> , 2015, 61, 1798-1808.	3.6	127
100	Differential expression of miRNAs in the visceral adipose tissue of patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 487-497.	1.9	126
101	Depression, anemia and health-related quality of life in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 491-498.	1.8	124
102	Caffeine is protective in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 76-82.	1.9	123
103	Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 801-814.	1.9	122
104	Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 853-861.	1.9	122
105	Review: Treatment options for nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 121-137.	1.4	119
106	Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C. <i>Psychosomatics</i> , 2011, 52, 127-132.	2.5	118
107	Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014, 60, 530-537.	1.8	118
108	Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. <i>Diabetes Care</i> , 2020, 43, 283-289.	4.3	115

#	ARTICLE	IF	CITATIONS
109	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
110	MELD fails to measure quality of life in liver transplant candidates. <i>Liver Transplantation</i> , 2005, 11, 218-223.	1.3	113
111	Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. <i>Liver Transplantation</i> , 2006, 12, 1381-1389.	1.3	110
112	Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 759-766.e5.	2.4	110
113	Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). <i>Health and Quality of Life Outcomes</i> , 2016, 14, 18.	1.0	109
114	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 544-563.	1.9	108
115	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 518-531.	1.9	107
116	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
117	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	0.8	105
118	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 33-39.	1.8	103
119	Economic model of a birth cohort screening program for hepatitis C virus. <i>Hepatology</i> , 2012, 55, 1344-1355.	3.6	102
120	Obesity and Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 705-709.	1.1	101
121	Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 421-428.	2.0	101
122	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	3.6	101
123	Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. <i>Liver International</i> , 2005, 25, 760-771.	1.9	100
124	Diagnosis and Management of Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 48-63.	0.2	100
125	Gene Expression of Leptin, Resistin, and Adiponectin in the White Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. <i>Obesity Surgery</i> , 2006, 16, 1118-1125.	1.1	98
126	Health-related quality of life in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 815-820.	1.9	98



#	ARTICLE	IF	CITATIONS
127	Impact of non-alcoholic fatty liver disease on chronic hepatitis B. <i>Liver International</i> , 2007, 27, 607-611.	1.9	96
128	Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. <i>BMC Molecular Biology</i> , 2010, 11, 39.	3.0	94
129	Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021, 75, 795-809.	1.8	94
130	Impact of liver transplantation on health-related quality of life. <i>Liver Transplantation</i> , 2000, 6, 779-783.	1.3	92
131	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	0.8	92
132	Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 1601-1604.	0.2	91
133	Evaluation and management of obesity-related nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 432-441.	1.7	90
134	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 298-312.	1.4	90
135	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. <i>Journal of Hepatology</i> , 2014, 61, 228-234.	1.8	88
136	Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). <i>Journal of Hepatology</i> , 2014, 60, 741-747.	1.8	88
137	Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1349-1359.e13.	2.4	87
138	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	2.5	87
139	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	2.5	87
140	The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 286-295.	1.9	86
141	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	3.6	86
142	Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States. <i>Hepatology</i> , 2011, 53, 737-745.	3.6	85
143	An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. <i>American Journal of Gastroenterology</i> , 2016, 111, 808-816.	0.2	85
144	Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017, 67, 940-949.	1.8	85

#	ARTICLE	IF	CITATIONS
145	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 1-10.	1.0	85
146	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100305.	2.6	83
147	A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 897-905.	1.0	80
148	Outcome of De Novo hepatitis C virus infection in heart transplant recipients. <i>Hepatology</i> , 1999, 30, 1293-1298.	3.6	79
149	Association of Chronic Liver Disease with Depression: A Population-Based Study. <i>Psychosomatics</i> , 2013, 54, 52-59.	2.5	79
150	Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 3-14.	1.9	79
151	Global burden of NAFLD and chronic liver disease among adolescents and young adults. <i>Hepatology</i> , 2022, 75, 1204-1217.	3.6	78
152	Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?. <i>Hepatology</i> , 2022, 76, 1423-1437.	3.6	78
153	Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. <i>Hepatology</i> , 2014, 59, 2161-2169.	3.6	77
154	Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. <i>Clinical Diabetes</i> , 2019, 37, 65-72.	1.2	77
155	Obesity-Associated Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 19-31.	1.0	75
156	Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. <i>Pharmacoeconomics</i> , 2015, 33, 1245-1253.	1.7	75
157	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	1.8	74
158	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	1.8	73
159	The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85,000 liver transplant recipients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 686-694.	1.9	72
160	A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. <i>Liver International</i> , 2017, 37, 1209-1218.	1.9	72
161	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	2.4	72
162	Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859.	1.9	72

#	ARTICLE	IF	CITATIONS
163	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	8.2	72
164	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 135-144.	0.4	70
165	Health-related quality of life in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 1119-1125.	1.9	69
166	Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 22-27.	1.0	69
167	Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. <i>American Journal of Medicine</i> , 2001, 111, 614-621.	0.6	68
168	Adherence to treatment of chronic hepatitis C. <i>Medicine (United States)</i> , 2016, 95, e4151.	0.4	68
169	Obesity-related Differential Gene Expression in the Visceral Adipose Tissue. <i>Obesity Surgery</i> , 2005, 15, 758-765.	1.1	67
170	Quality of Life in Cirrhosis. <i>Current Gastroenterology Reports</i> , 2013, 15, 301.	1.1	67
171	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	1.9	66
172	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	1.8	66
173	Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0. <i>Hepatology</i> , 2007, 46, 113-121.	3.6	65
174	A single non-invasive model to diagnose non-alcoholic fatty liver disease (<sc>NAFLD</sc>) and non-alcoholic steatohepatitis (<sc>NASH</sc>). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 2006-2013.	1.4	65
175	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019, 19, 56.	0.8	65
176	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
177	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262.	0.2	65
178	The epidemiology of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 92-94.	1.0	64
179	CHRONIC VIRAL HEPATITIS IN RENAL TRANSPLANT RECIPIENTS WITH ALLOGRAFTS FUNCTIONING FOR MORE THAN 20 YEARS <sup>1,2</sup> . <i>Transplantation</i> , 1999, 67, 272-275.	0.5	64
180	Effects of Weight Loss on Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2008, 28, 427-433.	1.8	63

#	ARTICLE	IF	CITATIONS
181	Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 479-484.	0.6	63
182	Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 703-709.	1.9	63
183	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132.	3.7	63
184	Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 254-260.	1.1	63
185	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. <i>Hepatology International</i> , 2019, 13, 205-213.	1.9	63
186	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.	1.9	62
187	Pathologic Assessment of Non-alcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2007, 11, 17-23.	1.0	61
188	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016, 64, 1893-1899.	3.6	61
189	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	0.6	60
190	Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. <i>Liver Transplantation</i> , 2008, 14, 321-326.	1.3	59
191	Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). <i>Journal of Translational Medicine</i> , 2013, 11, 133.	1.8	59
192	Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1132-1140.	1.1	58
193	The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, S186-S196.	0.4	58
194	Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000106.	1.1	58
195	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	0.6	58
196	13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY. <i>Journal of Hepatology</i> , 2011, 54, S6-S7.	1.8	57
197	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e11518.	0.4	57
198	Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience. <i>Clinical Infectious Diseases</i> , 2022, 74, 1063-1069.	2.9	57

#	ARTICLE	IF	CITATIONS
199	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1042-1048.	2.9	56
200	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.	1.9	56
201	Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. <i>Hepatology Communications</i> , 2020, 4, 1136-1148.	2.0	56
202	Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management. <i>Clinics in Liver Disease</i> , 2009, 13, 249-266.	1.0	55
203	Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 156-164.e3.	2.4	55
204	The Use of Growth Factors to Manage the Hematologic Side Effects of PEG-Interferon Alfa and Ribavirin. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S9-S13.	1.1	54
205	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377.	1.9	54
206	Economic Burden of Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 579-594.	1.0	54
207	The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. <i>Hepatology Communications</i> , 2020, 4, 1769-1780.	2.0	54
208	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. <i>Hepatology Communications</i> , 2021, 5, 1833-1847.	2.0	54
209	Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2020, 2, 100171.	2.6	54
210	Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States. <i>Hepatology Communications</i> , 2020, 4, 890-903.	2.0	53
211	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	0.6	53
212	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.	1.8	52
213	A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Hepatology</i> , 2015, 62, 1204-1206.	1.8	52
214	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. <i>Journal of Hepatology</i> , 2016, 65, S109-S119.	1.8	52
215	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 166-170.	1.3	52
216	Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. <i>Liver International</i> , 2009, 29, 3-12.	1.9	51

#	ARTICLE	IF	CITATIONS
217	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
218	The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. <i>Journal of Hepatology</i> , 2021, 75, S3-S13.	1.8	51
219	Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2007, 17, 1111-1118.	1.1	50
220	Nutritional Assessments of Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 154-160.	1.1	50
221	Hepatitis C Virus Infection and Coronary Artery Disease Risk: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1586-1593.	1.1	50
222	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the <scp>SIRIUS</scp> study. <i>Liver International</i> , 2016, 36, 42-48.	1.9	50
223	Disparate access to treatment regimens in chronic hepatitis <scp>C</scp> patients: data from the <scp>TRIO</scp> network. <i>Journal of Viral Hepatitis</i> , 2016, 23, 447-454.	1.0	50
224	Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 63-71.	1.4	50
225	Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2011, 21, 1750-1757.	1.1	49
226	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
227	A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. <i>Hepatology</i> , 2007, 46, 166-172.	3.6	48
228	Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 640-650.	1.1	48
229	Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 857-865.	1.0	48
230	The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). <i>Quality of Life Research</i> , 2008, 17, 575-584.	1.5	47
231	Chronic liver disease and health-related quality of life. <i>Gastroenterology</i> , 2001, 120, 305-307.	0.6	46
232	The Intestinal Microbiota and Liver Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012, 1, 9-14.	0.7	46
233	Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. <i>Liver International</i> , 2019, 39, 748-757.	1.9	46
234	Impact of Adherence on the Outcome of Antiviral Therapy for Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S23-S27.	1.1	45

#	ARTICLE	IF	CITATIONS
235	Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (<scp>CH</scp>â€œ) patients: an economic model from five European countries. <i>Journal of Viral Hepatitis</i> , 2016, 23, 217-226.	1.0	45
236	The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.	1.8	45
237	Epidemiology of Non-alcoholic Fatty Liver Disease in North America. <i>Current Pharmaceutical Design</i> , 2020, 26, 993-997.	0.9	45
238	Importance of fatigue and its measurement in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3669-3683.	1.4	45
239	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
240	Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis. <i>Obesity Surgery</i> , 2009, 19, 617-624.	1.1	44
241	Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. <i>Hepatology</i> , 2015, 61, 1471-1478.	3.6	44
242	Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1050-1060.	2.0	44
243	Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. <i>Journal of Viral Hepatitis</i> , 2012, 19, 341-345.	1.0	43
244	Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 222-227.	1.1	43
245	Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000096.	1.1	43
246	The impact of liver disease on health-related quality of life: A review of the literature. <i>Current Gastroenterology Reports</i> , 2002, 4, 79-83.	1.1	42
247	Treatment regimens for non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009, 8, S51-S59.	0.6	42
248	Superiority of Interferon-Free Regimens for Chronic Hepatitis C. <i>Medicine (United States)</i> , 2017, 96, e5914.	0.4	42
249	Healthâ€related quality of life in genotype 1 treatmentâ€naÃve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 124-133.	1.9	41
250	Pediatric Non-Alcoholic Fatty Liver Disease. <i>Children</i> , 2017, 4, 48.	0.6	41
251	Sofosbuvir and velpatasvir with or without voxilaprevir in directâ€acting antiviralâ€naÃve chronic hepatitis C: patientâ€reported outcomes from POLARIS 2 and 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 259-267.	1.9	41
252	Predictors of nonalcoholic steatohepatitis and significant fibrosis in nonâ€obese nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 332-341.	1.9	41

#	ARTICLE	IF	CITATIONS
253	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	2.4	41
254	Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. <i>Hepatology</i> , 2009, 49, 763-774.	3.6	40
255	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020, 115, 1496-1504.	0.2	40
256	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1240-1247.e5.	2.4	40
257	Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. <i>Hepatology</i> , 2018, 68, 2405-2412.	3.6	39
258	Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 459-467.	1.1	39
259	The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013. <i>JAMA Internal Medicine</i> , 2014, 174, 1407.	2.6	38
260	The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172.	1.9	38
261	Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. <i>Hepatology Communications</i> , 2019, 3, 74-83.	2.0	38
262	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 342-352.	1.9	38
263	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	1.8	38
264	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. <i>Hepatology Communications</i> , 2021, 5, 1676-1688.	2.0	38
265	Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2838-2847.e7.	2.4	38
266	The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008, 47, 373-375.	3.6	37
267	Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 386-393.	1.3	37
268	The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 291-304.	1.9	37
269	Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?. <i>Gastroenterology</i> , 2002, 123, 375-378.	0.6	36
270	Anger Experiences Among Hepatitis C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life. <i>Psychosomatics</i> , 2007, 48, 223-229.	2.5	36



#	ARTICLE	IF	CITATIONS
271	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. <i>Hepatology</i> , 2011, 54, 1167-1178.	3.6	36
272	Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. <i>Value in Health</i> , 2016, 19, 544-551.	0.1	36
273	Effectiveness of 8 or 12 weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 540-548.	1.9	36
274	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019, 114, 1636-1641.	0.2	36
275	Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. <i>Hepatology Communications</i> , 2022, 6, 3062-3072.	2.0	36
276	Non-alcoholic fatty liver disease and hepatitis C infection. <i>Minerva Gastroenterologica E Dietologica</i> , 2006, 52, 135-43.	2.2	36
277	Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 718-723.	2.4	35
278	Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 181-185.	0.4	35
279	Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. <i>Annals of Medicine</i> , 2015, 47, 40-46.	1.5	35
280	Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 623-630.	1.0	35
281	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	2.4	35
282	Metabolic Syndrome after Laparoscopic Bariatric Surgery. <i>Obesity Surgery</i> , 2008, 18, 1278-1286.	1.1	34
283	Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 550-555.	1.0	34
284	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , 2016, 95, e2702.	0.4	34
285	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. <i>Liver International</i> , 2018, 38, 258-265.	1.9	34
286	Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 452-453.	2.4	34
287	A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. <i>Journal of Viral Hepatitis</i> , 2008, 15, 370-378.	1.0	33
288	Expression of genes for microRNA processing enzymes is altered in advanced non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1410-1415.	1.4	33

#	ARTICLE	IF	CITATIONS
289	Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. <i>Psychosomatics</i> , 2018, 59, 567-574.	2.5	33
290	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2093-2100.e3.	2.4	33
291	Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2021, 4, e2123923.	2.8	33
292	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. <i>Medicine (United States)</i> , 2016, 95, e5048.	0.4	32
293	Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 565-578.	1.0	32
294	Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. <i>Liver International</i> , 2019, 39, 1661-1671.	1.9	32
295	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	2.0	32
296	Nonalcoholic fatty liver disease and the epidemic of obesity.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 657-664.	0.6	32
297	Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. <i>Annals of Hepatology</i> , 2022, 27, 100556.	0.6	32
298	A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries. <i>Value in Health</i> , 2010, 13, 128-131.	0.1	31
299	The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1065-1075.	1.9	31
300	Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. <i>BMC Gastroenterology</i> , 2014, 14, 208.	0.8	31
301	Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 676-685.	1.9	31
302	Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2017, 21, 739-753.	1.0	31
303	Real-world outcomes of ledipasvir/sofosbuvir in treatment-naïve patients with hepatitis C. <i>American Journal of Managed Care</i> , 2016, 22, SP205-11.	0.8	31
304	Vietnamese community screening for hepatitis B virus and hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2011, 18, 70-76.	1.0	30
305	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. <i>Journal of Hepatology</i> , 2016, 64, 29-36.	1.8	30
306	Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. <i>Liver International</i> , 2017, 37, 1796-1804.	1.9	30

#	ARTICLE	IF	CITATIONS
307	Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018, 27, 1513-1520.	1.5	30
308	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	4.3	30
309	Nonalcoholic fatty liver disease. <i>Current Gastroenterology Reports</i> , 1999, 1, 57-62.	1.1	29
310	High Rates of Uninsured Among HCV-Positive Individuals. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 826-830.	1.1	29
311	The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. <i>Liver International</i> , 2013, 33, 1281-1286.	1.9	29
312	Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. <i>Journal of Viral Hepatitis</i> , 2015, 22, 137-145.	1.0	29
313	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). <i>BMC Medical Genetics</i> , 2016, 17, 63.	2.1	29
314	Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1641-1649.e6.	2.4	29
315	Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 112-116.	0.9	29
316	Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1354-1361.e7.	2.4	29
317	Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2005, 9, 617-634.	1.0	28
318	The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2007, 11, 209-220.	1.0	28
319	Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. <i>BMJ Open</i> , 2014, 4, e004318.	0.8	28
320	The outcomes of adult liver transplants in the United States from 1987 to 2013. <i>Liver International</i> , 2015, 35, 2036-2041.	1.9	28
321	Real-world use of elbasvir/grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1511-1522.	1.9	28
322	Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 965-973.e2.	2.4	28
323	Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 453-461.	0.2	28
324	Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. <i>Hepatology Communications</i> , 2022, 6, 1506-1515.	2.0	28

#	ARTICLE	IF	CITATIONS
325	Clinical predictors of fibrosis in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1085-1094.	1.9	27
326	Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease. <i>Current Molecular Medicine</i> , 2010, 10, 166-172.	0.6	27
327	Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patients with Hepatic Encephalopathy. <i>Clinical Drug Investigation</i> , 2011, 31, 213-220.	1.1	27
328	Nonalcoholic fatty liver disease and bariatric surgery. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 163-171.	1.4	27
329	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015, 15, 175.	0.8	27
330	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1144-1147.	2.4	27
331	Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. <i>Liver International</i> , 2019, 39, 54-59.	1.9	27
332	A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 331-341.	1.1	27
333	Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. <i>Hepatology International</i> , 2020, 14, 556-566.	1.9	27
334	Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 449-453.	1.0	26
335	Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.	2.0	26
336	Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3248-3251.	1.1	25
337	Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). <i>BMJ Open Gastroenterology</i> , 2018, 5, e000198.	1.1	25
338	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 567-574.e6.	2.4	25
339	Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 68-78.	1.3	25
340	The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 1714-1715.	0.2	25
341	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	1.5	25
342	The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. <i>Hepatology Communications</i> , 2021, 5, 749-759.	2.0	25

#	ARTICLE	IF	CITATIONS
343	Health-related quality of life (HRQL) in chronic liver disease. <i>Digestive and Liver Disease</i> , 2005, 37, 819-820.	0.4	24
344	Overall health-related quality of life in patients with end-stage liver disease. <i>Clinical Liver Disease</i> , 2015, 6, 9-14.	1.0	24
345	Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. <i>BMC Gastroenterology</i> , 2016, 16, 137.	0.8	24
346	Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017, 66, 46-56.	3.6	24
347	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.	1.0	24
348	Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. <i>Journal of Infectious Diseases</i> , 2018, 217, 1033-1043.	1.9	24
349	Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 644-653.	1.9	24
350	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
351	Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014, 13, 533-540.	0.6	23
352	Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 271-278.	1.9	23
353	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naïve patients. <i>Liver International</i> , 2016, 36, 189-197.	1.9	23
354	Dermatologic Manifestations of Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 555-564.	1.0	23
355	The comprehensive outcomes of hepatitis C virus infection: A multifaceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-14.	1.0	23
356	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022, 4, 100525.	2.6	23
357	Emerging therapies for hepatitis C virus. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 535-544.	1.0	22
358	The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. <i>Journal of Translational Medicine</i> , 2012, 10, 25.	1.8	22
359	Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.	1.3	22
360	Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. <i>Liver International</i> , 2015, 35, 1367-1372.	1.9	22

#	ARTICLE	IF	CITATIONS
361	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	1.3	22
362	Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. <i>Clinical Transplantation</i> , 2016, 30, 1570-1577.	0.8	22
363	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.	1.1	22
364	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. <i>Hepatology</i> , 2018, 68, 155-165.	3.6	22
365	Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020, 40, 685-693.	1.9	22
366	Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 629-636.	1.4	22
367	Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. <i>Hepatology Communications</i> , 2022, 6, 90-100.	2.0	22
368	Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 207-215.	1.4	21
369	Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis. <i>Journal of Proteome Research</i> , 2010, 9, 3218-3224.	1.8	21
370	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.	3.6	21
371	Mortality associated with alcohol-related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 596-602.	1.9	21
372	Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States. <i>American Journal of Gastroenterology</i> , 2017, 112, 1700-1708.	0.2	21
373	Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2695-2706.	1.4	21
374	French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. <i>Value in Health</i> , 2018, 21, 1218-1225.	0.1	21
375	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.	2.9	21
376	Treating Medicaid patients with hepatitis C: clinical and economic impact. <i>American Journal of Managed Care</i> , 2017, 23, 107-112.	0.8	21
377	Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2014, 93, 470-476.	0.7	20
378	Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. <i>BMC Gastroenterology</i> , 2016, 16, 45.	0.8	20

#	ARTICLE	IF	CITATIONS
379	Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. <i>Psychosomatics</i> , 2016, 57, 82-88.	2.5	20
380	Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2018, 25, 354-362.	1.0	20
381	Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. <i>Hepatology Communications</i> , 2018, 2, 1227-1234.	2.0	20
382	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2020, 55, 330-341.	2.3	20
383	Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.	1.8	19
384	Markers of endothelial dysfunction in patients with nonalcoholic fatty liver disease and coronary artery disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1528-1534.	1.4	19
385	Inpatient Economic and Mortality Assessment for Liver Transplantation. <i>Transplantation</i> , 2014, 97, 98-103.	0.5	19
386	Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1317-1326.	1.0	19
387	Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 25.	1.0	19
388	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1087-1094.e2.	2.4	19
389	Waist-to-calf circumference ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1082-1091.	1.4	19
390	Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. <i>PLoS ONE</i> , 2018, 13, e0204772.	1.1	19
391	Nonalcoholic Steatohepatitis Is Becoming a Top Indication for Liver Transplantation Worldwide. <i>Liver Transplantation</i> , 2019, 25, 10-11.	1.3	19
392	Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2017, 16, 555-564.	0.6	18
393	Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. <i>Journal of Viral Hepatitis</i> , 2018, 25, 945-951.	1.0	18
394	Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. <i>Hepatology</i> , 2019, 69, 237-244.	3.6	18
395	A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. <i>Hematology</i> , 2019, 24, 679-719.	0.7	18
396	Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019, 39, 1837-1844.	1.9	18

#	ARTICLE	IF	CITATIONS
397	Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021, 10, R240-R247.	0.8	18
398	Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. <i>Journal of Viral Hepatitis</i> , 2015, 22, 977-982.	1.0	17
399	The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17,000 HCV-infected transplant recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 209-217.	1.9	17
400	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	1.9	17
401	Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020, 159, 1558-1560.e2.	0.6	17
402	Outcomes of liver transplantation by insurance types in the United States. <i>American Journal of Managed Care</i> , 2020, 26, e121-e126.	0.8	17
403	The metabolic syndrome and nonalcoholic fatty liver disease. <i>Panminerva Medica</i> , 2006, 48, 41-8.	0.2	17
404	Validation of the chronic liver disease questionnaire in Serbian patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 4950.	1.4	16
405	Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1060-1068.	1.9	16
406	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017, 37, 662-668.	1.9	16
407	Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881150.	1.4	16
408	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	1.0	16
409	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 468-476.e11.	2.4	16
410	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	2.0	16
411	Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis. <i>Endocrine Practice</i> , 2022, 28, 204-213.	1.1	16
412	Microarray technology in the study of obesity and non-alcoholic fatty liver disease. <i>Liver International</i> , 2005, 25, 1091-1096.	1.9	15
413	Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. <i>Liver International</i> , 2009, 29, 1403-1412.	1.9	15
414	African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, e62-e65.	1.1	15



#	ARTICLE	IF	CITATIONS
415	Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example. PLoS ONE, 2013, 8, e56009.	1.1	15
416	Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. Journal of Viral Hepatitis, 2015, 22, 8-17.	1.0	15
417	Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. Journal of Viral Hepatitis, 2017, 24, 789-796.	1.0	15
418	Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). PLoS ONE, 2018, 13, e0199294.	1.1	15
419	Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. BMC Gastroenterology, 2019, 19, 27.	0.8	15
420	Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. Clinical and Translational Gastroenterology, 2021, 12, e00340.	1.3	15
421	Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. Journal of Sports Medicine and Physical Fitness, 2019, 59, 1376-1388.	0.4	15
422	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	3.6	15
423	Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics, 2007, 7, 195-205.	1.5	14
424	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (United States), 2016, 95, e4243.	0.4	14
425	Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. Clinical Diabetes, 2017, 35, 79-83.	1.2	14
426	Patient-Reported Outcomes for Patients With Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 793-799.	2.4	14
427	Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. Alimentary Pharmacology and Therapeutics, 2018, 47, 680-688.	1.9	14
428	Exercise as an intervention for patients with end-stage liver disease. Medicine (United States), 2018, 97, e12774.	0.4	14
429	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2021, 31, 2002-2010.	1.1	14
430	Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. Gastroenterology, 2021, 160, 1845-1846.e3.	0.6	14
431	Management of nonalcoholic fatty liver disease in the Middle East. World Journal of Gastroenterology, 2020, 26, 3528-3541.	1.4	14
432	Evidence-based medicine: A method for solving clinical problems in hepatology. Hepatology, 1999, 30, 829-832.	3.6	13

#	ARTICLE	IF	CITATIONS
433	Pegylated Interferon $\hat{\pm}$ -2b, Ribavirin and Amantadine for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2005, 50, 970-975.	1.1	13
434	Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2014, 13, 84-90.	0.6	13
435	Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. <i>Medicine (United States)</i> , 2016, 95, e2482.	0.4	13
436	Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 123-128.	1.9	13
437	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1608-1616.	1.0	13
438	Development and validation of a hepatitis Bâ€specific healthâ€related qualityâ€ofâ€life instrument: CLDQâ€HBV. <i>Journal of Viral Hepatitis</i> , 2021, 28, 484-492.	1.0	13
439	Agreement in Pathologic Interpretation of Liver Biopsy Specimens in Posttransplant Hepatitis C Infection. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 143-145.	1.2	13
440	Non-Alcoholic Fatty Liver Disease After Liver Transplantation: A Case of Nurture and Nature. <i>American Journal of Gastroenterology</i> , 2010, 105, 621-623.	0.2	12
441	Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). <i>Brain and Behavior</i> , 2012, 2, 525-531.	1.0	12
442	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2505-2515.	1.1	12
443	Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 313-315.	2.4	12
444	The epidemiologic characteristics, temporal trends, predictors of death, and discharge disposition in patients with a diagnosis of sepsis: A cross-sectional retrospective cohort study. <i>Journal of Critical Care</i> , 2017, 39, 48-55.	1.0	12
445	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 228-235.	1.0	12
446	Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1641-1642.e1.	2.4	12
447	Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. <i>Scientific Reports</i> , 2020, 10, 6800.	1.6	12
448	Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. <i>Annals of Hepatology</i> , 2021, 22, 100277.	0.6	12
449	A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. <i>Panminerva Medica</i> , 2012, 54, 29-37.	0.2	12
450	Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006â€“2016. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz509.	0.4	11

#	ARTICLE	IF	CITATIONS
451	Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). <i>Journal of Proteome Research</i> , 2011, 10, 774-779.	1.8	10
452	Comparison of activity level among patients with chronic liver disease. <i>Disability and Rehabilitation</i> , 2013, 35, 907-912.	0.9	10
453	Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 320-332.	1.1	10
454	The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. <i>Journal of Viral Hepatitis</i> , 2016, 23, 53-61.	1.0	10
455	Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. <i>PM and R</i> , 2016, 8, 28-34.	0.9	10
456	Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. <i>Gastroenterology</i> , 2017, 152, 1588-1598.	0.6	10
457	Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. <i>Journal of Neuroimmunology</i> , 2019, 335, 577022.	1.1	10
458	Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to Action. <i>Hepatology</i> , 2021, 73, 1570-1580.	3.6	10
459	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.	2.4	10
460	Treatment strategies for chronic hepatitis C prior to and following liver transplantation. <i>World Journal of Hepatology</i> , 2016, 8, 69.	0.8	10
461	The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. <i>Seminars in Liver Disease</i> , 1999, 19 Suppl 1, 95-102.	1.8	10
462	Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014, 13, 533-40.	0.6	10
463	Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CHC). <i>Journal of Viral Hepatitis</i> , 2012, 19, 414-422.	1.0	9
464	Interaction of Type 2 diabetes and nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 405-407.	1.4	9
465	Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2015, 62, 761-762.	1.8	9
466	Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis. <i>Quality of Life Research</i> , 2017, 26, 1777-1784.	1.5	9
467	The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection. <i>Annals of Hepatology</i> , 2017, 16, 342-348.	0.6	9
468	Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. <i>Life</i> , 2021, 11, 799.	1.1	9

#	ARTICLE	IF	CITATIONS
469	Chronic hepatitis C: a clinical overview. <i>Cleveland Clinic Journal of Medicine</i> , 1997, 64, 259-268.	0.6	9
470	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
471	Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 730-736.	1.0	8
472	Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. <i>Hepatology</i> , 2012, 55, 968-970.	3.6	8
473	Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. <i>Annals of Hepatology</i> , 2014, 13, 60-64.	0.6	8
474	Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 249-267.	1.0	8
475	A New Comorbidity Model for Predicting Mortality in Patients With Cirrhosis: Does It Work?. <i>Gastroenterology</i> , 2014, 146, 19-24.	0.6	8
476	What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?. <i>Clinical Liver Disease</i> , 2015, 6, 117-119.	1.0	8
477	Vaccination against hepatitis A and B in patients with chronic liver disease and type 2 diabetes: has anything changed?. <i>Liver International</i> , 2016, 36, 1096-1100.	1.9	8
478	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). <i>Value in Health</i> , 2018, 21, 612-621.	0.1	8
479	An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 170.	2.3	8
480	Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. <i>Hepatology Communications</i> , 2019, 3, 356-364.	2.0	8
481	Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. <i>Clinical Infectious Diseases</i> , 2020, 70, 628-632.	2.9	8
482	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100280.	2.6	8
483	Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 169-174.	0.7	8
484	Long-term improvement in health-related quality of life after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1404-1405.	1.3	7
485	Novel treatment strategies for patients with nonalcoholic fatty liver disease. <i>Clinical Investigation</i> , 2011, 1, 229-239.	0.0	7
486	Natural history of nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2012, 1, 112-113.	1.0	7

#	ARTICLE	IF	CITATIONS
487	<scp>HCV</scp> infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015, 29, 920-926.	0.8	7
488	The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). <i>Medicine (United States)</i> , 2016, 95, e5066.	0.4	7
489	Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. <i>Liver International</i> , 2019, 39, 1631-1640.	1.9	7
490	Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2019, 98, e16704.	0.4	7
491	Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. <i>JHEP Reports</i> , 2021, 3, 100236.	2.6	7
492	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	1.5	7
493	Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1239-1248.	0.5	7
494	Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2013, 13, 84-90.	0.6	7
495	Impact of hepatitis C virus and insurance coverage on mortality. <i>American Journal of Managed Care</i> , 2019, 25, 61-67.	0.8	7
496	Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins. <i>Clinics in Liver Disease</i> , 2009, 13, 477-486.	1.0	6
497	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced <scp>HCV</scp> genotype 1 patients: <scp>REALIZE</scp> study. <i>Liver International</i> , 2015, 35, 448-454.	1.9	6
498	Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 659-665.	0.7	6
499	Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 416-422.	1.1	6
500	Liver Transplant Center Size and the Impact on Clinical Outcomes and Resource Utilization. <i>Transplantation</i> , 2022, 106, 988-996.	0.5	6
501	The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2915-2917.e1.	2.4	6
502	Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-4.	0.7	6
503	Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	5
504	Chronic HCV infection, diabetes and liver-related outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 520-521.	8.2	5

#	ARTICLE	IF	CITATIONS
505	Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, 72.	0.8	5
506	Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1293-1300.	1.0	5
507	Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 693-698.	1.1	5
508	Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time?. <i>Gastroenterology</i> , 2020, 158, 40-42.	0.6	5
509	The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. <i>Cancer Medicine</i> , 2021, 10, 6273-6281.	1.3	5
510	Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system. <i>PLoS ONE</i> , 2022, 17, e0263417.	1.1	5
511	Chronic Hepatitis B and D. , 0, , 26-38.		4
512	Hepatic Stellate Cell and Myofibroblast-Like Cell Gene Expression in the Explanted Cirrhotic Livers of Patients Undergoing Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 496-504.	1.1	4
513	Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors. <i>PM and R</i> , 2012, 4, 436-441.	0.9	4
514	Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 900-908.	1.4	4
515	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	1.1	4
516	Fatigue and Hepatitis C: a focus group study. <i>Qualitative Research in Medicine &amp; Healthcare</i> , 2017, 1, .	0.2	4
517	The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD). <i>Current Gastroenterology Reports</i> , 2018, 20, 24.	1.1	4
518	Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2018, 17, 11-13.	0.6	4
519	Association of Parity in Patients with Chronic Liver Disease. <i>Annals of Hepatology</i> , 2018, 17, 1035-1041.	0.6	4
520	The impact of sustained virologic response on severe fatigue in patients with chronic hepatitis C: The role of HCV viremia and co-morbidities. <i>Journal of Hepatology</i> , 2018, 68, S531.	1.8	4
521	Disparities in Access to Direct Acting Antiviral Regimens for Hepatitis C Virus (HCV): The Impact of Race and insurance Status. <i>American Journal of Gastroenterology</i> , 2018, 113, 1285-1286.	0.2	4
522	Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. <i>Liver International</i> , 2020, 40, 308-318.	1.9	4

#	ARTICLE	IF	CITATIONS
523	Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 63-73.	2.0	4
524	Adipokines in Non-Alcoholic Fatty Liver Disease. , 2007, , 291-305.		4
525	Evaluating asymptomatic patients with mildly elevated liver enzymes. <i>Cleveland Clinic Journal of Medicine</i> , 1998, 65, 150-158.	0.6	4
526	Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S253-S257.	1.4	3
527	Monitoring and treatment of inactive chronic hepatitis B: Is it cost-effective?. <i>Hepatology</i> , 2014, 60, 19-21.	3.6	3
528	The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?. <i>Clinical Liver Disease</i> , 2015, 6, 126-128.	1.0	3
529	Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas. <i>Hepatic Oncology</i> , 2016, 3, 101-103.	4.2	3
530	FATIGUE IN JAPANESE PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH LEDIPASVIR AND SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN. <i>Value in Health</i> , 2016, 19, A316-A317.	0.1	3
531	The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. <i>Hepatology</i> , 2018, 67, 1160-1162.	3.6	3
532	The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2018, 17, 345-349.	0.4	3
533	Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 262-268.	1.1	3
534	Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 58-64.	1.1	3
535	Hepatitis C update: Implications of the blood transfusion "lookback". <i>Cleveland Clinic Journal of Medicine</i> , 1998, 65, 412-422.	0.6	3
536	Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 16-22.	0.7	3
537	Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 612-622.	0.8	3
538	Service line care delivery model for COVID-19 patient-centric care. <i>American Journal of Managed Care</i> , 2022, 28, e80-e87.	0.8	3
539	Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1026-1034.	1.1	3
540	Selective Digestive Decontamination and its Use in Patients with Liver Disease. <i>Disease Management and Health Outcomes</i> , 1998, 4, 17-26.	0.3	2

#	ARTICLE	IF	CITATIONS
541	Nonalcoholic steatohepatitis. Current Treatment Options in Gastroenterology, 2004, 7, 423-430.	0.3	2
542	Reply to the Letter to the Editor: "Biomarker Biopsy" for the Diagnosis of NASH: Promises from CK-18 Fragments" by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. Obesity Surgery, 2008, 18, 1509-1510.	1.1	2
543	Commentary: phlebotomy in nonalcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 1112-1112.	1.9	2
544	Current management of patients with nonalcoholic fatty liver disease. Expert Review of Endocrinology and Metabolism, 2013, 8, 549-558.	1.2	2
545	Adipokines in Nonalcoholic Fatty Liver Disease. , 2014, , 249-283.		2
546	Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States. Emerging Infectious Diseases, 2016, 22, 565-567.	2.0	2
547	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. Health and Quality of Life Outcomes, 2016, 14, 49.	1.0	2
548	Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease. , 2016, , 21-40.		2
549	Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians. Journal of Hepatology, 2020, 73, S440.	1.8	2
550	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1299-1300.	2.4	2
551	Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clinical Gastroenterology and Hepatology, 2022, 20, e1149-e1156.	2.4	2
552	Validation of CLDQ-HCV as a Health Related Quality of Life (HRQL) Instrument for Patients with Chronic Hepatitis C (CH-C). American Journal of Gastroenterology, 2012, 107, S159.	0.2	2
553	Chronic kidney disease in patients with chronic hepatitis C virus infection. Minerva Gastroenterologica E Dietologica, 2018, 64, 376-382.	2.2	2
554	Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. Annals of Hepatology, 2013, 13, 60-4.	0.6	2
555	Response to Letters to the Editors. Hepatology, 2022, , .	3.6	2
556	A pharmacoeconomic appraisal of therapies for hepatitis B and C. Expert Opinion on Pharmacotherapy, 2001, 2, 205-211.	0.9	1
557	Complications of Cirrhosis. , 0, , 215-234.		1
558	Chronic Hepatitis C. , 0, , 39-60.		1



#	ARTICLE	IF	CITATIONS
559	HIV and Viral Hepatitis. , 0, , 61-76.		1
560	Response to the Letter from Ms. Tamzin Furtado. Value in Health, 2010, 13, 508.	0.1	1
561	Reply:. Hepatology, 2011, 54, 370-371.	3.6	1
562	OPO3 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. Gut, 2011, 60, A50-A51.	6.1	1
563	Commentary: physical activity and <scp>NAFLD</scp> â€•cause or effect? Authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 1098-1099.	1.9	1
564	Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral. Alimentary Pharmacology and Therapeutics, 2013, 38, 557-558.	1.9	1
565	Obesity and Liver Disease. Clinics in Liver Disease, 2014, 18, xiii-xiv.	1.0	1
566	Reply to â€œDebilitating fatigue as a treatment indication in chronic hepatitis Câ€• Journal of Hepatology, 2015, 63, 1534-1535.	1.8	1
567	Reply. Hepatology, 2016, 64, 1391-1393.	3.6	1
568	Nonalcoholic Steatohepatitis and Liver Transplantation. Current Hepatology Reports, 2016, 15, 113-116.	0.4	1
569	Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug - authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 841-842.	1.9	1
570	603 Access to Therapy in Era of All DAA Regimens: Real-World Experience From the TRIO Network. Gastroenterology, 2016, 150, S1040.	0.6	1
571	Quality of Life in Patients with Cirrhosisâ€™ Measurement and Clinical Impact. Current Hepatology Reports, 2018, 17, 15-21.	0.4	1
572	559 - Factors Associated with Progressive Course of Patients with Primary Biliary Cholangitis in the United States: Data from a Large-Real World Database. Gastroenterology, 2018, 154, S-1097.	0.6	1
573	SAT-269-The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who donâ€™t achieve sustained virologic response. Journal of Hepatology, 2019, 70, e753.	1.8	1
574	Sa1612 â€œ Mortality Related to Non-Alcoholic Fatty Liver Disease is Increasing in the United States Over the Last Decade. Gastroenterology, 2019, 156, S-1253.	0.6	1
575	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 2383-2384.	2.4	1
576	Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease. Journal of Clinical Hypertension, 2020, 22, 1915-1923.	1.0	1

#	ARTICLE	IF	CITATIONS
577	Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD" Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 712-712.	1.9	1
578	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
579	Quality of Life in Hepatic Encephalopathy. , 2012, , 221-231.		1
580	Health-Related Quality of Life and Health Care Resource Utilization in Patients With Chronic Liver Disease and Primary Liver Cancer in the United States: Analysis of Medical Expenditure Panel Survey. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 272-277.	0.4	1
581	The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 970-977.e1.	2.4	1
582	Reply:. <i>Hepatology</i> , 2007, 46, 1306-1307.	3.6	0
583	Reply:. <i>Liver International</i> , 2008, 28, 286-287.	1.9	0
584	Alpha-1 Antitrypsin Deficiency and the Liver. , 0, , 140-154.		0
585	Acute Viral Hepatitis. , 0, , 1-25.		0
586	Autoimmune Liver Disease. , 0, , 155-173.		0
587	Benign and Malignant Tumors of the Liver. , 0, , 195-214.		0
588	Genetic Hemochromatosis and Iron Overload. , 0, , 117-130.		0
589	Drug-Induced Liver Disease (DILI). , 0, , 174-194.		0
590	Novel Technologies in Studying Chronic Liver Disease. , 2008, , 256-276.		0
591	Hepatitis C and metabolic syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 209-215.	1.2	0
592	OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study. <i>Gut</i> , 2011, 60, A55-A55.	6.1	0
593	Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis. <i>Obesity Surgery</i> , 2011, 21, 1318-1318.	1.1	0
594	Reply:. <i>Hepatology</i> , 2011, 53, 1400-1400.	3.6	0

#	ARTICLE	IF	CITATIONS
595	Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1116-1116.	1.9	0
596	Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: We need to get the models right". <i>Journal of Hepatology</i> , 2014, 61, 454-455.	1.8	0
597	Editorial: the association of hepatitis C virus infection and post-liver transplant diabetes " authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 489-489.	1.9	0
598	Letter: effects of hepatitis C infection on the post-lung transplant mortality " authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 768-769.	1.9	0
599	Preface. <i>Clinics in Liver Disease</i> , 2017, 21, xiii.	1.0	0
600	Reply. <i>Hepatology</i> , 2018, 68, 390-390.	3.6	0
601	Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection" Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 537-538.	1.9	0
602	Reply. <i>Hepatology</i> , 2018, 67, 450-451.	3.6	0
603	A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS. <i>Journal of the Canadian Association of Gastroenterology</i> . 2018. 1. 307-308.	0.1	0
604	Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes. <i>Current Hepatology Reports</i> , 2018, 17, 459-465.	0.4	0
605	Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives. <i>Liver International</i> , 2018, 38, 1331-1331.	1.9	0
606	Validation of the chronic liver disease questionnaire for non-alcoholic steatohepatitis in patients: impact for the clinic. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 709-710.	1.4	0
607	Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e341-e347.	1.1	0
608	IDDF2019-ABS-0131...Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
609	The Burden of NAFLD Worldwide. , 2020, , 15-24.		0
610	Patient-Reported Outcomes in Hepatitis C Infection. , 2021, , 213-219.		0
611	Reply to Bailly, et al. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	0
612	Markers of Insulin Resistance during HVC Treatment: A Relationship to Sustained Virologic Response. <i>FASEB Journal</i> , 2010, 24, 659.4.	0.2	0

#	ARTICLE	IF	CITATIONS
613	Reply. Hepatology, 2022, 75, 1663-1664.	3.6	0
614	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€”Occam's razor applied to advanced fibrosis screening. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1761-1761.	1.9	0